Intellia Therapeutics (NASDAQ:NTLA) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Intellia Therapeutics (NASDAQ:NTLA) issued its quarterly earnings results on Thursday. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11), FiscalAI reports. The business had revenue of $7.16 million for the quarter, compared to analyst estimates of $9.74 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm’s quarterly revenue was down 47.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.92) EPS.

Intellia Therapeutics Stock Up 2.3%

Intellia Therapeutics stock opened at $11.35 on Friday. The business’s 50-day moving average price is $12.09 and its two-hundred day moving average price is $13.05. The stock has a market cap of $1.59 billion, a PE ratio of -3.39 and a beta of 1.83. Intellia Therapeutics has a 12-month low of $7.95 and a 12-month high of $18.48.

Insiders Place Their Bets

In related news, CEO John M. Leonard sold 9,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total transaction of $107,910.00. Following the completion of the transaction, the chief executive officer directly owned 1,138,064 shares of the company’s stock, valued at $13,645,387.36. This trade represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on NTLA shares. Wedbush lifted their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Evercore upgraded shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, August 7th. Finally, Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $21.05.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.